Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study
Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study
复制标题
DOI：
10.1007/s00266-020-01916-7
复制
发表时间：
2020-08-19
影响因子：
2.4
通讯作者：
Nasimi, Maryam
中科院分区：
文献类型：
--
作者：
Abedini, Robabeh;Rayeni, Neda Mehdizade;Nasimi, Maryam
背景技术疤痕是外科手术不可避免的结果，其预防仍然是美容外科领域的一大难题。尽管针对A型肉毒杆菌毒素（BoNT-A）注射预防增生性疤痕进行了各种研究，但其确切机制仍不清楚。方法这项前瞻性、双盲、随机研究对2018年10月至2019年12月在Razi医院接受乳房整形和腹部整形手术的19名患者进行。单次治疗，其中XEOMIN分配到疤痕的一半，将 0.9% 盐水添加到对照一半中。 3 个月和 6 个月后，使用改良的 Stony Brook 疤痕评估量表 (SBSES) 评估疤痕。 结果 总共分析了 19 名完成研究的患者。第三个月（P 值 < 0.001；3.34 +/- 1.59 与 1.5 +/- 1.36）和第 6 个月（P 值 < 0.001；4.89 +/- 1.83 与 2.39 +/- 1.82）的 mSBSES 显示治疗组和对照组之间存在显着差异。在子集分析中，第 3 个月和第 6 个月时，BoNT-A 与对照组在宽度、高度、颜色和疤痕可见度等所有四个项目上均存在显着差异，并且 BoNT-A 治疗侧在所有项目上得分较高。 结论 与安慰剂相比，BoNT-A 对预防乳房成形术和腹部成形术引起的疤痕具有显着效果，可减少红斑、高度、宽度并减少切口线可见度。此外，从第 3 个月到第 6 个月，其效果会随着时间的推移而显着增加。 证据级别 II 该期刊要求作者为每篇文章分配一个证据级别。有关这些循证医学评级的完整说明，请参阅目录或在线作者须知 www.springer.com/00266。
Background Scars are inevitable results of surgical procedures, and prevention of them is still a major problem in the field of cosmetic surgery. Although various studies have been performed on botulinum toxin-A (BoNT-A) injection for the prevention of hypertrophic scars, the exact mechanism remains unclear.Methods This prospective, double-blinded, randomized study was performed on 19 patients who underwent mammoplasty and abdominoplasty surgery in Razi Hospital from October 2018 to December 2019. Single session of treatment was performed, where XEOMIN was allocated to one half of the scar and 0.9% saline to the control half. 3 and 6 months later, scars were assessed using the modified Stony Brook Scar Evaluation Scale (SBSES).Results In total, 19 patients who completed the study were analyzed. mSBSES at the third month (P value < 0.001; 3.34 +/- 1.59 vs 1.5 +/- 1.36) and the sixth month (P value < 0.001; 4.89 +/- 1.83 vs 2.39 +/- 1.82) showed a significant difference between the treatment and control groups. In the subset analysis, there was significant difference between BoNT-A and control in all four items including width, height, color, and scar visibility at months 3 and 6, and the BoNT-A-treated sides had higher scores in all items.Conclusion BoNT-A has a significant effect on scar prevention due to mammoplasty and abdominoplasty compared to placebo and results in decreased erythema, height, width and reduces incision line visibility. Moreover, its effect increases significantly over time from months 3 to 6.Level of Evidence II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.